United States· US:0074-3878_6abe012f-69ad-4af5-8aeb-51b77acd6fba
EMBLAVEO
A medicinal product containing aztreonam; avibactam, registered in United States by AbbVie Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- AZTREONAM; AVIBACTAM
- Manufacturer
- AbbVie Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 2, 2026
Packs & prices · 1
- ndc110074-3878-10
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aztreonam; avibactam in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEMBLAVEOPfizer Europe MA EEIG, Bruxelles
- SpainEMBLAVEO 1,5 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPfizer Europe Ma Eeig
- FinlandEmblaveoPfizer Europe MA EEIG
- FranceEMBLAVEO 1,5 g/0,5 g, poudre pour solution à diluer pour perfusionPFIZER EUROPE MA EEIG (BELGIQUE)
- United KingdomEmblaveo 1.5g/0.5g powder for concentrate for solution for infusion vialsPfizer Ltd
- IrelandEmblaveo 1.5 g/0.5 g powder for concentrate for solution for infusionPfizer Europe MA EEIG
- NetherlandsEmblaveo 1,5 g/0,5 g poeder voor concentraat voor oplossing voor infusiePfizer Europe MA EEIG
- NorwayEmblaveoPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Emblaveo
- Liechtenstein · Emblaveo
- Norway · Emblaveo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7bc10837-2fa5-4b8e-8281-d39d539d82f0 GET /v1/drugs/7bc10837-2fa5-4b8e-8281-d39d539d82f0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "42.3; 127",
"substance": "AZTREONAM; AVIBACTAM",
"productndc": "0074-3878",
"dosage_form": "POWDER, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL; mg/mL",
"application_number": "NDA217906",
"marketing_category": "NDA"
}See everything about aztreonam; avibactam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.